Tamar Thompson
Director/Board Member bei AVIDITY BIOSCIENCES, INC.
Vermögen: - $ am 31.03.2024
Profil
Tamar Thompson is currently serving as the Chairman of the Alexion Charitable Foundation.
Additionally, Ms. Thompson holds the position of Independent Director at Catalyst Pharmaceuticals, Inc. since 2023, Independent Director at Avidity Biosciences, Inc. since 2021, and Vice President of US Government Affairs & Policy at Alexion Pharmaceuticals, Inc. since 2019.
Ms. Thompson previously worked at Bristol Myers Squibb Co. as the Head of Federal Executive Branch Strategy from 2015 to 2019.
Ms. Thompson obtained a graduate degree from Trident University International.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AVIDITY BIOSCIENCES INC
-.--% | 15.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Tamar Thompson
| Unternehmen | Position | Beginn |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Director/Board Member | 11.01.2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.11.2019 |
| CATALYST PHARMACEUTICALS, INC. | Director/Board Member | 25.05.2023 |
| Alexion Charitable Foundation | Chairman | - |
Ehemalige bekannte Positionen von Tamar Thompson
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.11.2019 |
Ausbildung von Tamar Thompson
| Trident University International | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CATALYST PHARMACEUTICALS, INC. | Health Technology |
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Alexion Charitable Foundation |
